Lenvatinib Plus Pembrolizumab, Pemetrexed, and a Platinum as First-Line Therapy for Metastatic Nonsquamous NSCLC: Phase 3 LEAP-006 Study. (Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025)